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Abstract 
Patients frequently experience a weight gain after organ transplantation. This increase in weight is the 
result of multiple factors, and is usually intensified by glucocorticoids and immunosuppressive drugs. It 
can also delay graft function and cause serious health problems. The objective of this study was to study 
the obesity as well as its causes and consequences in kidney transplant patients. The sample population 
consisted of 282 renal transplant patients, 170 men and 112 women, 18-74 years of age, who were 
monitored over a period of five years. For the purposes of our research, the patients were divided into 
two groups: (1) normal weight 18.5 ≤ BMI <25; (2) overweight 25 ≤ BMI ≤30. The association between 
BMI as an independent variable and graft survival was determined by means of a Cox regression analysis. 
Overweight patients were characterized by a higher comorbidity prevalence. In the Cox multivariate 
analysis, the initial BMI, evaluated as a continuous variable continued to be an independent predictor of 
delayed graft function and chronic nephropathy. This study evaluated the BMI as a continuous value 
instead of a categorical value. In conclusion, our results suggest that an increase in BMI without 
categorical variation can be an independent risk factor for graft loss. Consequently, obesity prevention 
for renal transplant patients should include dietary counseling and management, moderate physical 
activity, and steroid minimization. 
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Introduction 
Obesity is a serious risk factor for deteriorated 
kidney function in healthy people as well as for those 
with chronic kidney disease (CKD) [1]. Although the 
exact mechanisms that relate obesity to kidney disease 
are still unclear, it is believed that kidney damage is 
caused by hemodynamic and hormonal effects [2]. 
 Weight gain frequently occurs after a kidney 
transplant [3]. In all likelihood, an increased appetite 
and the easing of dietary restrictions because of 
hemodialysis and CKD, combined with immuno-
suppressive treatment and steroids, play an important 
role in this weight increase [4]. Various research 
studies indicate that kidney transplant recipients 
experience an average weight gain of 5-10 kgs, which 
is linked to a reduction in patient survival and graft 
failure [5-7]. 
Furthermore, this weight increment contributes 
to an adverse cardiovascular risk profile and could be 
implicated in the pathogenesis of graft dysfunction. 
The accumulation of abdominal fat can increase the 
inflammatory mediators produced by adipocytes, 
such as tumor necrosis factor alpha and interleukin-6, 
which contribute to interstitial and glomerular 
fibrosis. Obesity is associated with an increased rate of 
glomerular filtration, which over time eventually 
leads to glomerulosclerosis and the subsequent loss of 
kidney function. Moreover, hypertension caused by 
the activation of the sympathetic nervous system and 
renin-angiotensin system can also accelerate the loss 
of kidney function in obese patients [8,9]. 
Consequently, post-transplant weight gain is 








and ischemic heart disease [10]. Obesity-related risks 
in these patients include the following: (i) skin and 
soft-tissue complications, such as wound infection; (ii) 
anastomotic complications (lymphocele, hematoma 
and vascular); (iii) complications stemming from the 
intrinsic allograft function (delayed graft function, 
immune rejection, and graft survival); (iv) systemic 
complications (sepsis, hospital readmissions, post- 
transplant diabetes mellitus, and patient survival 
[11,12]. The aim of this retrospective study was to 
evaluate the effect of BMI on renal transplant outcome 
in the normal weight (NW) BMI: 18.5-24.9, and 
overweight (OW) BMI: 25–30, as well as the effect of 
immunosuppressive treatment over these 5 years after 
kidney transplantation. 
Materials and Methods 
Subjects 
The sample population consisted of 282 kidney 
transplant patients, 170 men and 112 women, 18-74 
years of age, who were being treated at the kidney 
transplant consultation of the Virgen de las Nieves 
University Hospital in Granada (Spain). The subjects 
were not randomly selected and their participation in 
the study was determined by the fact that they 
periodically visited the consultation for monitoring 
and check-ups. The patients were monitored over a 
period of five years. Exclusion criteria were (i) 
multi-organ transplantation, (ii) previous renal 
transplantation, (iii) patients <18 yr of age, (iv) obesity 
(BMI > 30), and (v) underweight (BMI < 18.5). BMI 
was calculated using weight and height at the time of 
transplantation. We excluded the obese and under- 
weight, as each circumstance is known to be a major 
risk for transplantation with associated confounding 
considerations [1]. 
Methods 
The immunosuppression regimen was the 
following: steroids (Ste) associated with 
mycophenolate mofetil (MMF), Tacrolimus (Tac), 
CD25, Cyclosporin A, and Thymoglobulin (TMG). 
During the first four weeks, the patients received 20 
mg/day of prednisone, administered in a single 
morning dose, which was progressively reduced until 
reaching a maintenance dose of 5-10 mg/day in the 
third month. The CsA dose, divided into two, was 
adjusted to maintain trough levels of 150-240 ng/ml 
during the first six months after transplant, and after 
that, trough levels of 100-150 ng/ml. The Tacrolimus 
dose, also divided into two, was adjusted to maintain 
levels of 10-15 ng/mL during the first three 
post-transplantation months, after which it was 
tapered down to 5-8 ng/ml. The MMF dose, divided 
into two, oscillated between 1-2 gr/day. 
In total, four combinations of immuno-
suppressive drugs were studied. The patients were 
divided into four groups, each of which received one 
of the following combinations of drugs: Group 1 [Ste 
+ MMF + Tac + CD25]; Group 2 [Ste + MMF + CsA + 
CD25]; Group 3: [St + MMF + Tac + TMG]; Group 4 
[Ste + MMf + Tac]. In addition, anthropometric 
measurements of weight and height were performed 
at 6, 12, 24, 36, 48 and 60 months with a balance/ 
stadiometer (Perperson 113481). Weight was 
measured in kilograms and height in centimeters. The 
body mass index was calculated with the following 
formula: BMI = weight (kg)/[height (m)]2. The 
patients were divided into two groups: (1) normal 
weight 18.5 ≤ BMI <25; (2) overweight 25 ≤ BMI ≤30. 
On their release from the hospital, the patients 
were instructed to consume 1.4-1.5 g/kg/day of diet 
protein (30-35 calories kcal/kg/day) during the first 
three months after the kidney transplant. 
Accordingly, they were told that lipids should not 
constitute more than 30% of the total diet, and that 
simple sugars should be avoided. After three months, 
the patients should reduce protein consumption to 1 
g/kg/day. 
All eligible patients gave informed consent to 
participate in the study, which was approved by the 
Human Ethics Committee of our Hospital. 
Statistical analysis 
Statistical analysis was carried out using the IBM 
SPSS Statics 20 software package. All values were 
expressed as frequencies, percentages, and means ± 
standard deviation (SD). A value of p < 0.05 was 
considered statistically significant. Continuous 
variables were compared using the Mann-Whitney U 
test, whereas categorical variables were compared 
using Fisher’s exact test (Table 1). 
 
Table 1. Characteristics of normal weight vs. overweight patients 
 Normal weight 
18.5 ≤BMI <25 
n=131 
Overweight 
25 ≤ BMI ≤30 
n=151 
p-value 
Graft recipient age (mean ± SD) 37.94 ±13.23 46.25 ± 12.64 0.000 
Gender: Male/Female % 55 / 45 65.3 / 34.7 NS 
Dialysis (years) 3.07 ± 3.31 2.74 ± 2.76 NS 
Donor age (mean ± SD) 36.85 ± 18.02 41.72 ± 18.10 0.000 
HLA incompatibilities (≤ 3) n (%) 46 (35.4) 62 (41.9) NS 
Cold ischemic time (h) mean ± SD 17.19 (4.8) 17.46 (5) NS 
Delayed graft function n (%) 70 (53.8) 83 (55.3) 0.05 
Acute rejection n (%) 20 (15.3) 31(20.7) NS 
Chronic graft nephropathy n (%) 44 (33.6) 60 (40) 0.05 
Diabetes n (%) 31 (23.7) 45 (30) 0.05 
Hypertension n (%) 109 (83.2) 123 (82) NS 
Mann-Whitney U test and Fisher’s exact test. Recipient age and kidney donor age 
are significantly greater in the overweight group as compared to the normal weight 
group. In contrast, there are no significant differences regarding dialysis time and 
gender. NS: not significant. 
 
 




To evaluate overweight as a risk factor of kidney 
deterioration, a Cox regression was used with a 
confidence interval of 95%. The variables in the 
analysis were the following: graft recipient age, 
gender, BMI, dialysis time, kidney donor age, chronic 
allograft nephropathy, acute rejection, delayed graft 
function, diabetes, and hypertension (Tables 3 & 4). 
Analysis of variance (ANOVA) was used to evaluate 
the differences between weight and immuno-
suppression treatment (Table 2). All data were 
expressed as means ± standard deviation (X ± SD). A 
value of p < 0.05 was considered statistically 
significant. 
 
Table 2. Comparison of mean weights by immunosuppressive 
medication groups. Anova Test 
  Mean Standard deviation Minimum Maximum 
Initial 
weight 
Group 1 68.45 11.30 41 97 
Group 2 68.33 6.74 56 77.5 
Group 3 68.57 17.68 44 97 
Group 4 66.70 12 41 98 
Year 1 Group 1 74.48 12.83 50.1 112 
Group 2 74.96 8.93 5.6 91 
Group 3 76.48 17.35 49.7 109.5 
Group 4 71.52 11.27 53.8 94.5 
Year 2 Group 1 73.73 15.67 13.8 104 
Group 2 75.76 8.48 59.0 92.7 
Group 3 77.02 18.07 48.5 107.8 
Group 4 70.95 12,50 46.7 96.2 
Year 3 Group 1 73.42 11.48 43.2 94.2 
Group 2 77.30 10.25 59.2 95.6 
Group 3 76.99 16.19 46.6 102 
Group 4 71.60 12.64 55.8 100.5 
Year 4 Group 1 73.73 11.53 47.0 93 
Group 2 77.24 7.20 68.1 88.2 
Group 3 76.88 15.60 56.0 105.6 
Group 4 71.77 13.00 56.7 105.6 
Year 5 Group 1 73.00 11.1 51.5 94 
Group 2 76.36 8.18 66.1 87.7 
Group 3 82.58 15.39 60.9 106.3 
Group 4 74.54 14.65 54.5 108.0 
All groups experienced an average weight gain of 5.5 kg from the first month after 
transplant until the end of the first year. After that, their weight continued to 
steadily increase during the following post-transplant years until reaching an 
average gain of 6.8 kg at the end of the fifth year. This increment was particularly 
striking in Group 3 in which the five-year weight gain was 14 kg as well as in 
Group 4, in which the gain was 9 kg. 
Group 1: Ste + MMF + Tac + CD25; Group 2: Ste + MMF + CsA + CD25; 
Group 3: Ste + MMF + Tac + TMG; Group 4: Ste + MMf + Tac. 
 
Results 
The mean age of the sample population was 
44.09 ± 14.04 years; mean weight was 66.24 ± 13.77 Kg; 
and mean BMI was 25 ± 4.62 Kg/m2. As can be 
observed, these mean values of weight (Figure 1) and 
BMI (Figure 2) significantly increased from the first to 
the fifth year after transplant. Table 1 shows the 
characteristics of the patient and graft after his/her 
classification as normal weight or overweight. As 
reflected in the table, recipient age and kidney donor 
age are significantly greater in the overweight group 
as compared to the normal weight group. In contrast, 
there are no significant differences regarding dialysis 
time and gender. 
 
Table 3. Univariate hazard ratios (95% CI): five-year graft failure 
 Univariate 
Graft recipient age 1.027 (1.020-1.035)* 
Gender (male vs. female) 0.852 (0.703-1.030) 
Initial BMI 1.101 (1.080-1.122)* 
Initial BMI (overweight vs. normal weight) 2.289 (1.890-2.772)* 
Dialysis time (years) 0.979 (0.948-1-010) 
Donor age 1.015 (1.010-1.021)* 
Delayed graft function  1.151 (0.953-1.390) 
Chronic graft nephropathy 1.297 (1.071-1.570)* 
Acute rejection 0.897 (0.710-1-134) 
Diabetes 1.322 (1.081-1.617)* 
Hypertension 1.005 (0.790-1.279) 
*p < 0.01. The variables that showed a significant correlation between overweight 
and post-transplant outcome in the univariate analysis were the following: graft 
recipient age, BMI, kidney donor age, chronic graft nephropathy and diabetes. 
 
 
Table 4. Multivariate hazard ratios (95% CI): five-year graft failure 
 Multivariate 
Graft recipient age 1.011 (1.002-1.021)* 
Donor age 1.009 (1.003-1.015)* 
BMI of graft recipient 1.082 (1.058-1.107)* 
Delayed graft function  0.684 (0.493-0.949)* 
Chronic graft nephropathy 1.462 (1.053-2.028)* 
Acute rejection 0. 985 (0.771-1-258) 
Diabetes 0.92 (0.742-1.155) 
Hypertension 0.861 (0.671-1.106) 
*p < 0.01. The analysis indicated a significant correlation between overweight and 
graft recipient age, kidney donor age, and initial BMI, which were evaluated as 
continuous variables, and delayed kidney function and chronic graft nephropathy, 
which were evaluated as categorical variables. Graft rejection, hypertension, and 
diabetes were also included in the Cox regression model. 
 
 
In relation to the characteristics of the graft, the 
results showed a significantly high prevalence of 
chronic graft nephropathy, diabetes and delayed graft 
function. The same thing occurs with hypertension, 
number of HLA incompatibilities, and acute rejection 
though the differences are not statistically significant. 
The cold ischemia time was similar in both groups of 
patients. 
In regard to the immunosuppressant treatments, 
all groups experienced an average weight gain of 5.5 
kg from the first month after transplant until the end 
of the first year. After that, their weight continued to 
steadily increase during the following post-transplant 
years until reaching an average gain of 6.8 kg at the 
end of the fifth year. This increment was particularly 
striking in Group 3 in which the five-year weight gain 
was 14 kg as well as in Group 4, in which the gain was 
9 kg (Table 2). 
The variables that showed a significant 
correlation between overweight and post-transplant 
outcome in the univariate analysis were the following: 




graft recipient age, BMI, kidney donor age, chronic 
graft nephropathy, and diabetes (Table 3). 
 
 
Figure 1. Evolution of the mean annual values of the weight in the simple 
population. As can be observed, these mean values of weight significantly increased 
from the first to the fifth year after transplant. 
 
Figure 2. Evolution of the mean annual values of the Body Mass Index in 
the simple population. As can be observed, these mean values of BMI significantly 
increased from the first to the fifth year after transplant. 
 
The results of the Cox multivariate analysis 
indicated a significant correlation between over-
weight and graft recipient age, kidney donor age, and 
initial BMI, which were evaluated as continuous 
variables, and delayed kidney function and chronic 
graft nephropathy, which were evaluated as 
categorical variables. Graft rejection, hypertension, 
and diabetes were also included in the Cox regression 
model (Table 4). 
Discussion 
This study analyzed 282 kidney transplant 
patients to determine the causes and consequences of 
obesity and its prevalence. The results obtained 
showed a high prevalence of overweight patients, 
which increased from the first to the fifth year after 
the transplant. As can be observed, there was a 
significant gain in weight and BMI after the graft 
(Figures 1 & 2). This is a serious problem since during 
the post-transplant period, obesity is an important 
risk factor for graft survival as well as for the 
development of cardiovascular diseases, hyper-
tension, diabetes, and dyslipidemias. Moreover it is a 
frequent cause of morbidity and mortality in these 
patients [13,14]. 
Nevertheless, the impact of obesity on graft 
survival is controversial [15, 16], since various studies 
have found that obesity does not affect the graft 
survival, despite higher rates of surgical 
complications [15, 17]. In the same line, other research 
also affirms that obesity does not portend a negative 
outcome for kidney transplant patients [19-22]. In our 
opinion, these studies may be biased to a certain 
extent, which would explain their results. More 
specifically, the methodological error could be they 
used WHO BMI ranges and did not analyze the BMI 
as a continuous variable. 
For this reason, our study analyzed the average 
BMI range (i.e. patients with a BMI of 18.5-30 kg/m2 
and excluded all patients with a BMI <18.5 (under-
weight) and a BMI> 30 (obese). We then evaluated 
whether the BMI, expressed as a continuous value, 
was a risk factor in the different categories. Our 
results showed that the BMI was significantly 
associated with chronic nephropathy and delayed 
graft function, including the patients within the same 
BMI category (normal weight as well as overweight 
patients). 
Moreover, the multivariate as well as the 
univariate analysis reflected a correlation between 
negative graft outcome and age, gender, BMI, delayed 
graft function, chronic nephropathy, acute rejection, 
hypertension, and diabetes. Furthermore, in the 
multivariate analysis with continuous BMI values, it 
was evident that the BMI was significantly associated 
with graft failure, independently of the co-variables, 
delayed graft function and chronic nephropathy, both 
of which are also implicated in a negative graft 
outcome [23-25]. 
Weight gain after transplant is very common. In 
fact, various authors even affirm that it is universal 
[26, 27]. These studies showed a weight gain of over 
20% in the first year and 10% in the second year, an 
increment directly related to a lower patient survival 
rate. This finding has been confirmed by a 
multicentric study carried out in the Netherlands, 
which found that the one-year post-transplant BMI 
and BMI increase were more strongly associated with 
death and graft failure than pre-transplant BMI 
among kidney transplant recipients [28]. 
This situation is a serious problem for clinical 
work and practice, given the potential consequences 
and difficulty in achieving and maintaining normal 
weight, [29-30]. In our study, the weight gain was 11% 
after one year and 20% after five years. This is similar 
to the results of other studies where the gain was 
10.9% after the first year and 15.3% at the end of five 
years [31, 32]. 




The etiopathogenesis of obesity in renal 
transplants is multifactorial, and many of the 
variables that affect the transplant are similar to those 
that affect the population in general (e.g. genetic and 
environmental factors, sedentary lifestyle, etc.) [33, 
34], however, we did not find any differences related 
to age, race or gender between the examined patients 
with respect to weight and BMI and graft responses. 
Other factors that are more specifically related to the 
transplant are patients’ uremic state, general health, 
and immunosuppression therapy [35,36]. 
Steroids are a key factor in weight gain because 
steroid ingestion leads to metabolic effects, 
redistribution of body fat, water retention, and above 
all, an increased appetite [37, 38]. As can be observed 
in this study, the four combinations of immuno-
suppressive drugs administered included steroids, 
and all led to a considerable weight gain during the 
five-year monitoring period. 
The prevention of weight gain after 
transplantation is managed by a multidisciplinary 
team with psychological support, who focus on 
helping patients to improve their dietary habits. More 
research is needed to evaluate how new immuno-
suppressive agents, steroid minimization strategies, 
and steroid-free immunosuppression will affect post- 
transplant outcomes in the obese populations. Some 
patients have opted for bariatric surgery. Despite the 
relatively small number of cases, the results are 
promising [39, 23]. These studies found that patients 
experienced a significant weight loss and an 
improvement in comorbidity without any serious 
graft rejection or dysfunction. However, these authors 
also warn that there is also a greater risk of surgical 
complications in transplanted patients in comparison 
to the general population. 
In conclusion, our study found that there was a 
high prevalence of post-transplant overweight and 
obesity during the first post-transplant year. The BMI 
was evaluated as a continuous value instead of as a 
categorical value. Our results indicated that an 
increment in BMI, without categorical variation, can 
be an independent risk factor for graft loss. After the 
first year, the BMI of the patients increased 2.5 Kg/m2 
and the weight 6.6 Kg. Consequently, obesity 
prevention for renal transplant patients should 
include dietary counseling and management, 
moderate physical activity, and steroid minimization. 
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